Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
Edward Gane(University of Auckland), Charles A. Robinson(Center for Global Development), Susan K. Lyman(Exelixis (United States)), Faouzi Saliba(Hôpital Paul-Brousse), John O'Grady(St James's University Hospital), Garcia Valdecasas(Hospital Clínic de Barcelona), Mark D. Pescovitz(University Medical Center)
Cited by 501
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Sjögren's syndrome. Proposed criteria for classification
|Arthritis & Rheumatism|1986|685
Oral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir Implant
|New England Journal of Medicine|1999|485
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
|New England Journal of Medicine|2002|394